Critical unresolved questions re: population dynamics of SARS-CoV-2 infectiousness and host immunity


The following critical but unresolved questions are an attempt to outline an urgent open scientific debate with expert scientists in virology, vaccinology and immunology, preferably in a joined constructive effort to find a way out of the ongoing world crisis.

More infectious variants

  • How to explain the sudden emergence of several, more infectious variants (e.g., UK, South-African, Brazilian variants) in QIV 2020 (i.e., prior to the roll-out of mass vaccination campaigns and despite relatively low infection rates)?


  • Will highly infectious variants persist in the human population? (How) can these variants be controlled? 


  • What is the likelihood for mutations rendering these variants less infectious and/or less virulent (cfr. ‘common cold’) to be selected? What would be the likelihood for such less infectious variants to adapt to the human population? 


Innate immunity

  • What is the contribution of variant-nonspecific innate immunity to anti-Covid-19 immune defense? 


  • Can spike(S)-specific antibodies (Abs) outcompete multimeric, variant-nonspecific sIgMs for binding to S protein? If so, can S-specific Abs interfere with natural Abs even if the former are unable to neutralize the virus? 


Asymptomatic infection

  • How to explain the increase in cases of severe Covid-19 disease in younger (< 60 years), previously protected, age groups as currently observed in several countries?

  • What is the role of short-lived anti-S Ab titers in a subset of asymptomatically infected subjects? Are those protective or do they interfere with the host’s innate immunity?

  • Which immune mechanisms prevent Sars-CoV-2 infections from causing (severe) symptoms in the vast majority of the population?

  • Which mechanisms are responsible for rapid viral clearance in asymptomatically infected subjects? 

  • To what extent do young healthy people contribute to the emergence of new variants?

Ongoing mass vaccination campaigns

  • What is the likelihood that ongoing mass vaccination campaigns will provide herd immunity? 


  • Which objective criteria could be considered reliable indicators of potential selective immune escape of Sars-CoV-2? How to investigate whether or not a correlation exists between these criteria and external influences such as those brought about by pharmaceutical or nonpharmaceutical interventions?

  • How would the expected impact of mass vaccination with a live attenuated Coronavirus compare to that of the ongoing mass vaccination campaigns? 




  • What is our current understanding of the mechanism causing ‘common cold’ coronaviruses to provide short-lived protection against Covid-19 disease? 


  • How can we explain re-infection with Sars-CoV-2 to occur in the presence of neutralizing Abs?


  • What is the role of CD8+ T cells in immune protection against Covid-19? 

  • What is currently known about the evolution of Ab titers and protection against more infectious viral variants in subjects who were enrolled in pivotal vaccine trials?